Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2000

View Archived Issues

Cambridge Antibody Technology reports recent developments

Despite positive phase II results, Medivir must seek new partner for ME-609

Herceptin enters phase III trial as adjuvant therapy in early-stage breast cancer

Health Canada clears Enbrel for moderately to severely active RA

FDA approves second indication for Antizol

FDA clearance allows Amarin to begin Huntington's disease trials

Plan B emergency contraceptive now available in Canada

Tamiflu approved in Japan

Altered peptide ligand agreement between Neurocrine Biosciences and Taisho expanded

Berlex now marketing Levulan Kerastick photodynamic therapy in U.S.

Bronchial effects of prostanoid DP antagonist reported at Japanese Society of Allergology meeting

Kaken presents dual LTD4 and TxA2 antagonist with promising antiasthmatic profile

In vitro and in vivo characterization of the newly synthesized thrombin inhibitor AT-1362

Merck & Co. obtains rights to Probiodrug's DP-IV inhibitors for diabetes

AstraZeneca's rosuvastatin will be sold as Crestor

CeNeS shareholders approve acquisition of Cambridge NeuroScience

New agent for atopic dermatitis is endowed with antihistaminic and antiinflammatory effects

Quinoxalinecarboxylic acid-based AMPA receptor antagonists with good solubility characteristics

SmithKline Beecham terminates lotrafiban clinical development

AHP and Ligand collaboration focuses on progesterone receptor modulators

Aza compounds synthesized at Georgetown U. inhibit monoamine neurotransmitter reuptake

Cardiovascular agents useful for hypertension and ischemic disorders discovered at CSIR

Recent Japanese patent reveals new TNF-alpha inhibitors from Snow Brand

Pola's new ACAT inhibitors described in patent literature

Taisho discovers new histamine H2 antagonist with antisecretory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...